ARCHIVES

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

This article is from The Cancer Letter archive.

Vol. 31 No. 22 | June 3, 2005

Download PDF Visit The Full Archive

Related Articles

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

July 25, 2008

NCI-Approved Clinical Trials

December 31, 2004

Anil Potti Reprimanded by North Carolina Licensure Board

December 9, 2011

New Mexico, Missouri, Columbia Next for Review As comprehensive Centers; UCLA Decision In October

September 17, 1976

Sledge Elected ASCO President

January 16, 2009

Budget Difficulties Aside, Centers Important To NCI, Broder Asserts; Warns Against Sabotage.

July 12, 1991